Literature DB >> 19054147

Significance of dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expressions in hepatocellular carcinoma.

Akira Nii1, Mitsuo Shimada, Toru Ikegami, Yukari Harino, Satoru Imura, Yuji Morine, Hirofumi Kanemura, Yusuke Arakawa, Koji Sugimoto.   

Abstract

AIM: The significance of dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) gene expressions for the post-surgical prognosis of hepatocellular carcinoma (HCC) has not yet been determined. In the present study, we clarified the significance of DPD and TS gene expressions for the prognosis of HCC.
METHODS: Seventy-four patients, who underwent curative hepatic resection for primary HCC, were evaluated. The DPD and TS mRNA levels of the resected HCC specimens were evaluated using a microdissection technique and quantative real-time RT-PCR. The patients were categorized into high and low groups for each mRNA based on the median value. Various clinicopathological factors, including prognosis, and proliferation index using Ki-67 staining were evaluated in association with the DPD and TS mRNA expression levels.
RESULTS: The low DPD mRNA expression was related to younger age, advanced clinical stage, undifferentiated histology, and microscopic intrahepatic metastasis. The overall and recurrence-free survival were significantly lower in the low DPD group than in the high DPD group (P < 0.05). Furthermore, the proliferation index in the low DPD group was significantly higher than that in the high DPD group (P < 0.01). On the other hand, the high TS group showed a tendency of better prognosis than the low TS group, although it was not statistically significant.
CONCLUSIONS: The low DPD mRNA expression is a significant poor prognostic factor. after curative resection of HCC.

Entities:  

Year:  2008        PMID: 19054147     DOI: 10.1111/j.1872-034X.2008.00457.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  6 in total

1.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.

Authors:  Yuji Morine; Mitsuo Shimada; Tohru Utsunomiya; Satoru Imura; Tetsuya Ikemoto; Jun Hanaka; Mami Kanamoto; Nobuhiro Kurita; Hidenori Miyake
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

2.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.

Authors:  Shuichi Iwahashi; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka
Journal:  Surg Today       Date:  2012-01-24       Impact factor: 2.549

3.  Elevated levels of mRNAs encoding dihydropyrimidine dehydrogenase and thymidylate synthase are associated with improved survival of patients with hepatocellular carcinoma treated with S-1.

Authors:  Yusuke Okano; Hidekazu Kuramochi; Go Nakajima; Satoshi Katagiri; Masakazu Yamamoto
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

4.  Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.

Authors:  Kohei Shigeta; Yoshiyuki Ishii; Hirotoshi Hasegawa; Koji Okabayashi; Yuko Kitagawa
Journal:  World J Surg       Date:  2014-12       Impact factor: 3.352

5.  Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Authors:  Nancy A Jenkins; Neal G Copeland; Emilie A Bard-Chapeau; Anh-Tuan Nguyen; Alistair G Rust; Ahmed Sayadi; Philip Lee; Belinda Q Chua; Lee-Sun New; Johann de Jong; Jerrold M Ward; Christopher Ky Chin; Valerie Chew; Han Chong Toh; Jean-Pierre Abastado; Touati Benoukraf; Richie Soong; Frederic A Bard; Adam J Dupuy; Randy L Johnson; George K Radda; Eric Cy Chan; Lodewyk Fa Wessels; David J Adams
Journal:  Nat Genet       Date:  2013-12-08       Impact factor: 38.330

6.  Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.

Authors:  Hongyun Zhao; Yuanyuan Zhao; Ying Guo; Yan Huang; Suxia Lin; Cong Xue; Fei Xu; Yang Zhang; Liping Zhao; Zhihuang Hu; Li Zhang
Journal:  Onco Targets Ther       Date:  2013-07-03       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.